Recent CE-IVD and coverage steps for specimen handling and MRD testing reflect an industry push to reduce operational friction in oncology trials. Personalis’ CE-IVD marking for blood collection kits is paired with Medicare coverage progress for NeXT Personal, supporting the assay’s use in late-stage monitoring. Standardizing pre-analytical workflows can be particularly important for ultrasensitive MRD tools where sample integrity directly affects detectability. The regulatory approvals therefore function as trial-enablement signals rather than standalone assay results. Taken together, these steps reinforce a pipeline-to-operations pattern: validate clinical utility, secure reimbursement and regulatory readiness, then scale specimen collection across multi-site studies.